This is a working overview of HGF/c-Met, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-25. Anything still debated is marked as such rather than presented as settled.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
The MNHN has been called "the Louvre of the Natural Sciences". Its largest and best-known gallery is the Grand Gallery of Evolution, located at the end of the central alley facing the formal garden. It replaced an earlier Neoclassical gallery built next to the same by Buffon, opened in 1785, and demolished in 1935. It was proposed in 1872 and begun in 1877 by the architect Louis-Jules André, a teacher at the influential École des Beaux-Arts in Paris. It is a prominent example of Beaux Arts Architecture. It was opened in 1889 for the Paris Universal Exposition of 1889, which also presented the Eiffel Tower. It was never fully completed in its original design; it never received the neoclassical entrance planned for the side of the building away from the garden, facing Rue Geoffroy-Saint-Hilaire. The facade of the building was designed specifically as a backdrop for the garden. The facade facing the garden is divided into eleven traverses. Ten are decorated with sculpted medallions honouring prominent French scientists associated with the MNHN. The central traverse has a larger marble statue of a woman seated holding a book, in a pose similar to that of statue of Buffon facing the building. The statues are the work of Eugene Guillaume, a pupil of the sculptor Pradier. While the building exterior was neo-classical, the iron framework of the interior was extremely modern for the 19th century, like that of the Gare d'Orsay railroad station of the same period.
Acids play important roles in the human body. The hydrochloric acid present in the stomach aids digestion by breaking down large and complex food molecules. Amino acids are required for synthesis of proteins required for growth and repair of body tissues. Fatty acids are also required for growth and repair of body tissues. Nucleic acids are important for the manufacturing of DNA and RNA and transmitting of traits to offspring through genes. Carbonic acid is important for maintenance of pH equilibrium in the body. Human bodies contain a variety of organic and inorganic compounds, among those dicarboxylic acids play an essential role in many biological behaviors. Many of those acids are amino acids, which mainly serve as materials for the synthesis of proteins. Other weak acids serve as buffers with their conjugate bases to keep the body's pH from undergoing large scale changes that would be harmful to cells. The rest of the dicarboxylic acids also participate in the synthesis of various biologically important compounds in human bodies.
=== Other contamination cases === On 4 October 1992, an El Al Boeing 747-F cargo aircraft (Flight 1862) crashed into an apartment building in Amsterdam, Netherlands. Local residents and rescue workers complained of various unexplained health issues, which were being attributed to the release of hazardous materials during the crash and subsequent fires. Authorities conducted an epidemiological study in 2000 of those believed to be affected by the accident. The study concluded that there was no evidence to link depleted uranium (used as counterbalance weights on the elevators of the plane) to any of the reported health complaints. There have been accidents involving uranium hexafluoride in the United States, including one in which 32 workers were exposed to a cloud of UF6 and its reaction products in 1986 at a Gore, Oklahoma, commercial uranium conversion facility. One person died; while a few workers with higher exposure experienced short-term kidney damage (e.g., protein in the urine), none of them showed lasting damage from the exposure to uranium.
Like other cluster decays, alpha decay is fundamentally a quantum tunneling process. Unlike beta decay, it is governed by the interplay between both the strong nuclear force and the electromagnetic force. Alpha particles have a typical kinetic energy of 5 MeV (or ≈ 0.13% of their total energy, 110 TJ/kg) and have a speed of about 15,000,000 m/s, or 5% of the speed of light. There is surprisingly small variation around this energy, due to the strong dependence of the half-life of this process on the energy produced. Because of their relatively large mass, the electric charge of +2 e and relatively low velocity, alpha particles are very likely to interact with other atoms and lose their energy, and their forward motion can be stopped by a few centimeters of air. Approximately 99% of the helium produced on Earth is the result of the alpha decay of underground deposits of minerals containing uranium or thorium. The helium is brought to the surface as a by-product of natural gas production.
== Actions == The Council announced a state of emergency in Port Sudan during tribal clashes which resulted in the death of 16 people on 26 August 2019. In November 2019, Abdalla Hamdok's government repealed all laws restricting women's freedom of dress, movement, association, work and study. On 22 April 2020, the transitional government issued an amendment to its criminal legislation which declares that anyone who performs female genital mutilation either in a medical establishment or elsewhere will be punished by three years' imprisonment and a fine.
Sources: en.wikipedia.org
==== Surface potential ==== The relation between surface charge and surface potential can be expressed by the Grahame equation, derived from the Gouy-Chapman theory by assuming the electroneutrality condition, which states that the total charge of the double layer must be equal to the negative of the surface charge. Using the one-dimensional Poisson equation and assuming that, at an infinitely great distance, the potential gradient is equal to 0, the Grahame equation is obtained:
Adorno, Theodor. Aesthetic Theory. Archived 8 July 2011 at the Wayback Machine University of Minnesota Press, 1996 Fieser, James; Dowden, Bradley (eds.). "Theodor Adorno". Internet Encyclopedia of Philosophy. ISSN 2161-0002. OCLC 37741658. Zuidervaart, Lambert. "Theodor W. Adorno". In Zalta, Edward N. (ed.). Stanford Encyclopedia of Philosophy. ISSN 1095-5054. OCLC 429049174. Illuminations – The Critical Theory Project Odysseus and the Siren Call of Reason: The Frankfurt School Critique of Enlightenment published in Other Voices, n.1 v.1, 1997. "Adorno during the 1950s" by Juergen Habermas Archived 7 February 2016 at the Wayback Machine Daniel Sherer, "Adorno's Reception of Loos: Modern Architecture, Aesthetic Theory, and the Critique of Ornament", Potlatch 3 (Spring 2014), 19–31. Sound recordings with Theodor W. Adorno in the Online Archive of the Österreichische Mediathek (Scientific lectures) (in German) Theodor W. Adorno discography at Discogs Review of Prisms (1955) The Boston Phoenix (1982)
=== Pharmaceutical excipients === Some pharmaceutical products require protection from oxidation. A number of antioxidants can be used as excipients. Sequestrants such as disodium EDTA can also be used to prevent metal-catalyzed oxidation.
==== MeSH E05.196.941 – ultracentrifugation ==== MeSH E05.196.941.336 – centrifugation, density gradient MeSH E05.196.941.336.253 – centrifugation, isopycnic MeSH E05.196.941.336.419 – centrifugation, zonal
The isotopic substitution changes the vibrational frequencies of various bonds in the molecule, which can have observable effects on the chemical reactivity via the kinetic isotope effect, and even by extension the biological activity in some cases.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.